Contineum Therapeutics, Inc. (CTNM)
17.02
-0.03
(-0.18%)
USD |
NASDAQ |
Aug 26, 16:00
17.04
+0.02
(+0.15%)
After-Hours: 20:00
Contineum Therapeutics Shareholders Equity (Quarterly) : 239.66M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 239.66M |
| March 31, 2026 | 250.04M |
| December 31, 2025 | 260.99M |
| September 30, 2025 | 180.47M |
| June 30, 2025 | 171.39M |
| March 31, 2025 | 184.77M |
| December 31, 2024 | 198.07M |
| September 30, 2024 | 210.23M |
| Date | Value |
|---|---|
| June 30, 2024 | 217.50M |
| March 31, 2024 | -75.63M |
| December 31, 2023 | -67.94M |
| September 30, 2023 | -61.14M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -93.21M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 1.044M |
| CNBX Pharmaceuticals, Inc. | -2.660M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 562.20M |
| Fulcrum Therapeutics, Inc. | 310.70M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 250.37M |
| Total Liabilities (Quarterly) | 10.71M |
| Debt to Equity Ratio | 0.0274 |
| Current Ratio | 37.17 |
| Net Debt Paydown Yield | -0.02% |